Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Mati Therapeutics Inc. Clear all
Completed Phase 2 Interventional

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

NCT00967811
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Formulation E1 of L-PPDS, Formulation E2 of L-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

NCT01037036
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Latanoprost Punctal Plug Delivery System, Xalatan
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 2, 2026, 5:04 PM EDT
Completed No phase listed Interventional Results available

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

NCT04962009
View directory record Official record
Conditions
Elevated Intraocular Pressure (IOP)
Interventions
Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

NCT04280653
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
NDE L68 StableFit® Punctal Plug
Device
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Edgewood, Kentucky • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

NCT03496467
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Nepafenac PPDS, Placebo PPDS
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT00650702
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT00845299
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT01481051
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension (OH)
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Artesia, California • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

NCT00821002
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Latanoprost
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

NCT00820300
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT01481077
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension (OH)
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 2, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

NCT02014142
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Latanoprost Punctal Plug Delivery System (L-PPDS)
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 2, 2026, 5:04 PM EDT